HAIXI PHARMA Allocates Idle Capital to Financial Products

Stock News

02/05

HAIXI PHARMA (02637) has announced that on October 24, 2025, Fujian Haixi New Drug Creation Co., Ltd., acting as an investor, utilized its idle funds to subscribe to (i) HKD 200 million worth of fund-linked notes (the Fund-Linked Notes) from the 2025-32 series, issued under the USD 1 billion guaranteed structured notes program by Essence Global Investment Limited; and (ii) up to HKD 200 million in China Rock Fund SPC. The subscription to China Rock Fund, together with the subscription to the Fund-Linked Notes, is referred to as the Subscriptions. The rational and effective use of temporarily idle funds is expected to enhance the company's capital returns. This move aligns with the company's core objective of ensuring fund security and liquidity while meeting the capital requirements for the group's daily operations and dividend distributions.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1136379883"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136379883\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136379883?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136379883","market":"sh","top_or_hot":-1,"title":"HAIXI PHARMA Allocates Idle Capital to Financial Products","media":"Stock News","content":"<p>HAIXI PHARMA (02637) has announced that on October 24, 2025, Fujian Haixi New Drug Creation Co., Ltd., acting as an investor, utilized its idle funds to subscribe to (i) HKD 200 million worth of fund-linked notes (the Fund-Linked Notes) from the 2025-32 series, issued under the USD 1 billion guaranteed structured notes program by Essence Global Investment Limited; and (ii) up to HKD 200 million in China Rock Fund SPC. The subscription to China Rock Fund, together with the subscription to the Fund-Linked Notes, is referred to as the Subscriptions. The rational and effective use of temporarily idle funds is expected to enhance the company's capital returns. This move aligns with the company's core objective of ensuring fund security and liquidity while meeting the capital requirements for the group's daily operations and dividend distributions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HAIXI PHARMA Allocates Idle Capital to Financial Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHAIXI PHARMA Allocates Idle Capital to Financial Products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-05 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HAIXI PHARMA (02637) has announced that on October 24, 2025, Fujian Haixi New Drug Creation Co., Ltd., acting as an investor, utilized its idle funds to subscribe to (i) HKD 200 million worth of fund-linked notes (the Fund-Linked Notes) from the 2025-32 series, issued under the USD 1 billion guaranteed structured notes program by Essence Global Investment Limited; and (ii) up to HKD 200 million in China Rock Fund SPC. The subscription to China Rock Fund, together with the subscription to the Fund-Linked Notes, is referred to as the Subscriptions. The rational and effective use of temporarily idle funds is expected to enhance the company's capital returns. This move aligns with the company's core objective of ensuring fund security and liquidity while meeting the capital requirements for the group's daily operations and dividend distributions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159940","symbol_name":"金融","start_time":0,"source_url":"","article_id":"1136379883","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136379883","pubTimestamp":1770280827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HAIXI PHARMA (02637) has announced that on October 24, 2025, Fujian Haixi New Drug Creation Co., Ltd., acting as an investor, utilized its idle funds to subscribe to (i) HKD 200 million worth of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159940":"金融","BK1191":"制药","02637":"海西新药"},"translate_title":"海西药业闲置资金配置理财产品","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159940":1,"02637":1},"content_text":"HAIXI PHARMA (02637) has announced that on October 24, 2025, Fujian Haixi New Drug Creation Co., Ltd., acting as an investor, utilized its idle funds to subscribe to (i) HKD 200 million worth of fund-linked notes (the Fund-Linked Notes) from the 2025-32 series, issued under the USD 1 billion guaranteed structured notes program by Essence Global Investment Limited; and (ii) up to HKD 200 million in China Rock Fund SPC. The subscription to China Rock Fund, together with the subscription to the Fund-Linked Notes, is referred to as the Subscriptions. The rational and effective use of temporarily idle funds is expected to enhance the company's capital returns. This move aligns with the company's core objective of ensuring fund security and liquidity while meeting the capital requirements for the group's daily operations and dividend distributions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}